123 related articles for article (PubMed ID: 20304314)
1. [Treatment of bone involvement in Gaucher diseases with imiglucerase combined with miglustat].
Marie I
Presse Med; 2009 Dec; 38 Suppl 2():2S68-70. PubMed ID: 20304314
[No Abstract] [Full Text] [Related]
2. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
3. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Hachulla E; Javier RM
Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
[No Abstract] [Full Text] [Related]
4. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
Javier RM; Hachulla E
Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
[TBL] [Abstract][Full Text] [Related]
5. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
[TBL] [Abstract][Full Text] [Related]
6. Gaucher disease: hematologic and oncologic implications.
Hughes D
Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
[No Abstract] [Full Text] [Related]
7. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
8. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
9. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
11. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
12. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
13. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
14. Extended remission of B-cell lymphoma with monoclonal gammopathy in a patient with type 1 Gaucher disease treated with enzyme replacement therapy.
Camou F; Viallard JF
Blood Cells Mol Dis; 2012 Jan; 48(1):51-2. PubMed ID: 21983348
[No Abstract] [Full Text] [Related]
15. [Therapeutic objectives in Gaucher disease].
Mistry P; Germain DP
Rev Med Interne; 2007 Oct; 28 Suppl 2():S171-5. PubMed ID: 18228683
[TBL] [Abstract][Full Text] [Related]
16. [Osteoarticular manifestations of Gaucher's Disease and imiglucerase efficacy on bone mineral density in adults. Review of literature].
Schaeverbeke T
Presse Med; 2009 Dec; 38 Suppl 2():2S38-41. PubMed ID: 20304304
[No Abstract] [Full Text] [Related]
17. [Cost reduction in the treatment of Gaucher s disease].
García Salom P; Acedo A
Farm Hosp; 2007; 31(3):194-5. PubMed ID: 17941761
[No Abstract] [Full Text] [Related]
18. [Clinical study of the French cohort of Gaucher disease patients].
Stirnemann J
Rev Med Interne; 2006 Mar; 27 Suppl 1():S18-21. PubMed ID: 16644396
[TBL] [Abstract][Full Text] [Related]
19. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic goals in Gaucher disease.
Mistry P; Germain DP
Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
